GlassScriptPhysician profile
Bharat Kumar Mehta
NPI 1033104484
$27,461.29
in general payments reported to CMS, 2019-2025
40 companies · $3,538 in 2025
The $3,538 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,257 · 2020: $2,051 · 2021: $4,847 · 2022: $4,437 · 2023: $3,831 · 2024: $2,501 · 2025: $3,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,606 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,605.76 |
| Education | $263.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,894.63 | 2019-2025 | Lokelma, Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $3,228.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novo Nordisk INC | $2,556.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $2,197.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,131.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $1,961.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Neurocrine Biosciences, INC. | $1,400.24 | 2022-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $1,221.59 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $936.97 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $714.82 | 2019-2022 | |
| Abbvie INC. | $660.59 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $625.86 | 2020-2025 | Caplyta |
| Abbott Laboratories | $590.40 | 2021-2023 | Infinity, Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $566.18 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $481.16 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharat Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.